TY - JOUR
T1 - Concise review
T2 - Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features
AU - Daughtry, Brittany
AU - Mitalipov, Shoukhrat
PY - 2014
Y1 - 2014
N2 - Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.
AB - Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.
KW - Histocompatibility
KW - Imprinting
KW - Parthenogenesis
KW - Pluripotent stem cells
UR - http://www.scopus.com/inward/record.url?scp=84896279403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896279403&partnerID=8YFLogxK
U2 - 10.5966/sctm.2013-0127
DO - 10.5966/sctm.2013-0127
M3 - Article
C2 - 24443005
AN - SCOPUS:84896279403
SN - 2157-6564
VL - 3
SP - 290
EP - 298
JO - Stem cells translational medicine
JF - Stem cells translational medicine
IS - 3
ER -